We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Spectral Medical Inc.
An SI Board Since October 2011
Posts SubjectMarks Bans Symbol
474 11 0 EDTXF
Emcee:  Sultan Type:  Unmoderated
Spectral is a Phase III company seeking U.S. FDA approval for its lead theranostics product for the treatment for severe sepsis and septic shock. Toraymyxin is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream. Directed by the Company's Endotoxin Activity Assay (EAA™), the only FDA cleared diagnostic for the risk of developing sepsis. Spectral's EUPHRATES trial is the world's first theranostics trial in the area of sepsis.

Toraymyxin has been approved for therapeutic use in Japan and Europe , and has been used safely and effectively in more than 80,000 patients to date. In March 2009, Spectral obtained the exclusive development and commercial rights in the U.S. for Toraymyxin, and in November 2010, signed an exclusive distribution agreement for this product in Canada . More than 250,000 patients are diagnosed with severe sepsis and septic shock in North America each year, representing a greater than $1 billion market opportunity for Spectral. Spectral is listed on the Toronto Stock Exchange under the symbol SDI.

For further information please visit
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
474Spectral Medical Inc. Announces Closing of Additional US$1 Million Convertible NSultan-yesterday
473Spectral Medical Inc. Announces Change to Auditor 11
472[graphic]Sultan-July 8
471Options exercised by insiders last couple of months Jun 4/24 Jun 3/24 Walker,Sultan-July 3
470Spectral Medical Provides June Tigris Trial Update 116 patients enrolled JuneSultan-July 2
469Blood perfusion with polymyxin B immobilized columns in patients with COVID-19 rSultan-June 4
468Winning the Battle against Septic Shock spectraldx.comSultan-May 26
467AGM on June 7th.. Only two items on proxy.. Election of Directors and Public AccSultan-May 24
466Spectral Medical Inc. Announces C$8.5 Million Bought Deal Convertible Note FinanSultan-May 10
465Spectral Medical Provides April Tigris Trial Update Spectral Medical Inc. Mon, Sultan-May 6
464Spectral Medical Provides Tigris Trial Update 10
463Spectral Medical Announces Fourth Quarter and Fiscal 2023 Results and Provides CSultan-April 3
462Spectral Medical Chair to Retire From the Board of Directors Dr. Paul Walker tSultan-April 3
461With only 57 patients to full enrollment, the Company is entering the final pushSultan-March 7
460On March 4, 2024, Baxter International Inc. (“Baxter”) provided an update on theSultan-March 5
459Raymond James Conference - Vantive and Today's 8-K Questioner Early last ySultan-March 5
458CRRT CONFERENCE 2024 CRRT Conference Breakfast Symposium Waking up to EndotoxeSultan-March 1
457Spectral Medical Provides February Tigris Trial Update 28
456February Presentation spectraldx.comSultan-February 24
455Spectral Medical Announces Amendment and Extension of Exclusive Supply and DistrSultan-February 21
454Spectral Medical Announces Major Milestone by Reaching Its Interim Enrollment TaSultan-February 15
453Spectral Medical Provides Early February Tigris Trial Update 5
452Just a little tidbit as a reminder while we were discussing Tigris Trial and theSultan-February 4
45142ND ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE Baxter is spinninSultan-January 12
450 Spectral Medical Provides Tigris Trial Update
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):